ApoE-null mice developed increased levels of cholesterol (VLDL and LDL), without alterations in triglyceride, when diabetes was induced. This differs from what usually occurs in human diabetes.

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver ...

The insulin was delivered with an electronic atomizer (Reger et al., 2008). A separate small trial comparing different doses in 33 people with aMCI or early AD reported differential effects by ApoE ...

Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...

This includes having Type 2 diabetes, obesity ... brain health remained regardless of whether people carried the APOE ε4 gene that makes someone more likely to develop dementia later in life.